Immutep announces first clinical data from 90mg dosing of efti

Immutep Limited announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha in combination with weekly paclitaxel in patients from the safety lead-in of the AIPAC-003 Phase II/III trial. Updated safety data from patients with HR-positive/HER2-negative/low metastatic breast cancer treated with this innovative immuno-oncology-chemotherapy combination reveal no treatment-emergent serious adverse events. Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity. Initial efficacy reports show these six MBC patients, who exhausted all endocrine therapy including cyclin-dependent kinase 4/6 inhibitors, exhibited encouraging results achieving a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall with the remaining three patients having stable disease as best response.